Skip to content
DataLookout
Menu

NCT07708727

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 16 → 21 locations
  2. Notable Primary endpoints: details revised at 3 of 3 entries Show 4 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Trial sites expanded: 11 → 16 locations
    • Interventions: B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug) to B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug)
    • Secondary endpoints: details revised at 3 of 19 entries
  3. Minor Trial sites expanded: 8 → 11 locationsv3
  4. Notable Recruitment opened
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Jul 2026 to Jul 29, 2026
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Timeframe: Week 35
Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm
Timeframe: Week 26
Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Timeframe: Week 52

Secondary (19)

Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA Snapshot Algorithm
Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Phase 2: Parts A and B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 12
Phase 2: Part A: Change From Baseline in CD4 Cell Count at Week 35
Phase 2: Parts A and B: Change From Baseline in CD4 Cell Count at Week 52
Show 14 moreShow less
Phase 2: Part B: Change From Baseline in CD4 Cell Count at Week 26
Phase 2: Parts A and B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 12
Phase 2: Part A: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 35
Phase 2: Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26
Phase 2: Parts A and B and Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 18
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 35
Phase 2: Part A and Part B: Trough Concentrations of GS-3242 and LEN at Week 52
Phase 2: Part B: Trough Concentrations of GS-3242 and LEN at Week 26
Phase 3: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 104 as determined by the US FDA snapshot algorithm
Phase 3: Change From Baseline in CD4 Cell Count at Week 52
Phase 3: Change From Baseline in CD4 Cell Count at Week 104
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 104

Arms and interventions

Phase 2: Part A: Group 1 of GS-3242 + LENExperimental

Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN for at least 52 weeks.

Phase 2: Part A: Group 2 of GS-3242 + LENExperimental

Participants will be randomized oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 (at a different dose than Group 1) and LEN for at least 52 weeks.

Phase 2: Part A: Group 3 of B/F/TAFExperimental

Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 52 weeks.

Phase 2: Part B: Group 4 of GS-3242 + LENExperimental

Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injections of GS-3242 and LEN (at different doses than Group 1 and 2) for at least 52 weeks.

Phase 3: Group 1 of GS-3242 + LENExperimental

Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 and LEN for at least 104 weeks.

Phase 3: Group 2 of B/F/TAFExperimental

Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 104 weeks.

Drugs: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF

Sites

21 sites in 5 countries

United States 15, Canada 2, Puerto Rico 2, Germany 1, Spain 1